Detalles de la búsqueda
1.
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Lancet Oncol
; 24(1): 77-90, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36493792
2.
Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1.
Oncologist
; 28(1): e77-e81, 2023 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36342342
3.
A review on the added value of whole-body MRI in metastatic lobular breast cancer.
Eur Radiol
; 32(9): 6514-6525, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35384456
4.
Impact of timing of adjuvant chemothapy for early breast cancer: the Royal Marsden Hospital experience.
Br J Cancer
; 125(2): 299-304, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34017085
5.
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer - Authors' reply.
Lancet Oncol
; 24(3): e104, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36858725
6.
Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer - Authors' reply.
Lancet Oncol
; 24(6): e238, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37146620
7.
Pneumonitis and pulmonary fibrosis associated with breast cancer treatments.
Breast Cancer Res Treat
; 146(2): 245-58, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24929676
8.
Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer.
Breast Cancer Res Treat
; 148(1): 221-9, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25288231
9.
The optimal duration of adjuvant endocrine therapy for early stage breast cancer--with what drugs and for how long?
Curr Oncol Rep
; 16(1): 358, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24390724
10.
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.
NPJ Breast Cancer
; 10(1): 34, 2024 Apr 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38671001
11.
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.
Eur J Cancer
; 199: 113555, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38244363
12.
A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.
Breast Cancer Res Treat
; 137(3): 755-66, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23283526
13.
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.
Breast Cancer Res Treat
; 137(2): 471-82, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23239151
14.
Adjuvant Systemic Therapy for Postmenopausal, Hormone Receptor-Positive Early Breast Cancer.
Hematol Oncol Clin North Am
; 37(1): 89-102, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36435616
15.
Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer.
NPJ Breast Cancer
; 9(1): 45, 2023 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37258523
16.
Imaging in metastatic breast cancer, CT, PET/CT, MRI, WB-DWI, CCA: review and new perspectives.
Cancer Imaging
; 23(1): 53, 2023 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37254225
17.
Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
Ther Adv Med Oncol
; 15: 17588359231151840, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36756142
18.
Endocrine treatment for ductal carcinoma in situ: balancing risks and benefits.
Lancet
; 387(10021): 819-21, 2016 Feb 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-26686312
19.
Case Report: Neratinib Therapy Improves Glycemic Control in a Patient With Type 2 Diabetes and Breast Cancer.
Front Endocrinol (Lausanne)
; 13: 830097, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35370966
20.
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.
JAMA Oncol
; 8(8): 1190-1194, 2022 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35653145